万赛维治疗效果怎样呢？

It is a prodrug of ganciclovir and is mainly used to treat cytomegalovirus retinitis and prevent CMV infection in high-risk solid organ transplant patients.

The recommended dose in adults with normal renal function, for the treatment of induction of cytomegalovirus retinitis: The recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily.

Common adverse reactions are: diarrhea, low white blood cell, red blood cell and platelet cell counts in blood tests, fever, fatigue, nausea, headache, insomnia, urinary tract infection, shaking movements (tremor), vomiting, etc., which usually gradually lessen as the medication is stopped.

Clinical studies of Valganciclovir in AIDS patients infected with CMV retinitis have shown that Valganciclovir tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the Vancevir tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week four was the same in both groups.

After induction therapy, both groups of patients in the study continued to receive maintenance therapy with Vancevir tablets at a dose of 900 mg per day. Among patients who received Vancevir tablets or intravenous ganciclovir induction therapy followed by Vancevir tablets maintenance therapy, the mean (median) time from randomization to progression of CMV retinitis was: 226 (160) days and 219 (125) days.

The clinical antiviral effect of the tablet has been demonstrated in the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). After four weeks of treatment with Vancevir tablets, the detection rate of CMV virus decreased from 46% (32/69) at study enrollment to 7% (4/55).